



European
Crohn's and Colitis
Organisation

Virtual

Inflammatory Bowel Diseases

Pocket Guide



17th Congress of ECCO
Virtual
February 16-19, 2022

www.ecco-ibd.eu

Key dates

February 14, 2022	ECCO'22 Virtual Congress Platform opens
February 16-18, 2022	Educational Programme
February 17-19, 2022	17 th Congress of ECCO 2022: Scientific Programme

ECCO Congress Office

February 14, 2022	09:00 - 17:00 CET
February 15, 2022	09:00 - 17:00 CET
February 16, 2022	07:00 - 19:00 CET
February 17, 2022	07:00 - 19:00 CET
February 18, 2022	07:00 - 19:00 CET
February 19, 2022	08:00 - 14:00 CET

About ECCO

ECCO strives for optimisation of care for patients with IBD in all aspects. As part of this mission ECCO adopts and furthers all efforts that lead to an improvement of the use of current therapies and procedures. Main aims include the development of guidelines with highest possible methodology and content quality and joint efforts to define better and more valid outcome parameters for the therapy of IBD.

Further aspects of the mission include the promotion of specialist, postgraduate education in IBD, as well as scientific projects in IBD. Such promotion can include intellectual input, funding and joint training using an ECCO defined curriculum. ECCO's visibility will always be as an organisation and not as the individuals making up ECCO. With all its activities the name of ECCO will stand in the world of gastroenterology for the highest possible level in quality and full impartiality in the results.

ECCO Office

Ungargasse 6/13
1030 Vienna, Austria
Phone: +43-(0)1-710 22 42
Fax: +43-(0)1-710 22 42-001
E-Mail: ecco@ecco-ibd.eu
Web: www.ecco-ibd.eu




European
Crohn's and Colitis
Organisation



European
Crohn's and Colitis
Organisation

ECCO IBD APP



The World of ECCO in your pocket

Features and Benefits:

- Listen to Audio Podcasts and watch Talking Heads on the go
- Discover the e-Guide
- Access ECCO News at any time
- Find more ECCO Initiatives at one glance
- Stay up-to-date in the IBD World
- Watch the ECCO'22 Congress on the go

Available in App Stores free of charge:



"Navigating the Oceans of IBD"

Thursday, February 17, 2022

Scientific programme day by day (as per February 9, 2022)

11:00 - 12:00	Industry Sponsored Satellite Symposia 1a, 1b, 1c, 1d
12:15 - 12:30	1: Opening L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
12:30 - 14:00	Scientific Session 1: Developing environmental recipes for IBD J. Colombel, New York, United States W. Reinisch, Vienna, Austria
12:30 - 12:50	2: What is the role of the environment in IBD? J. Lindsay, London, United Kingdom
12:50 - 13:00	3: OP01: Withdrawal of infliximab or anti-metabolite therapy in Crohn's Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE) E. Louis, Liège, Belgium
13:00 - 13:20	4: What environmental factors are modifiable? Lessons from non-IBD conditions B. Nemery de Belleaux, Leuven, Belgium
13:20 - 13:30	5: OP02: The breastmilk proteomics of women with Inflammatory Bowel Disease (IBD) and its impact on fecal calprotectin and microbiota composition in their babies J. Guedelha Sabino, Leuven, Belgium
13:30 - 13:40	6: OP03: Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study C. Caenepeel, Leuven, Belgium
13:40 - 14:00	7: Interventional trials addressing environmental factors in IBD J. Guedelha Sabino, Leuven, Belgium
14:00 - 14:30	Break

OP = Oral presentation – Best abstracts

14:30 - 16:00	Scientific Session 2: Keeping the patient at home: Is telemedicine the future? H. Gordon, London, United Kingdom M. Pierik, Maastricht, The Netherlands
14:30 - 14:50	8: I want to see my patient in person vs. I can manage my patient remotely G. Doherty, Dublin, Ireland R. Panaccione, Calgary, Canada
14:50 - 15:00	9: OP04: Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial S. Travis, Oxford, United Kingdom
15:00 - 15:20	10: Point of care testing N. Teix, Innsbruck, Austria H. Tilg, Innsbruck, Austria
15:20 - 15:30	11: OP05: Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study D. Turner, Jerusalem, Israel
15:30 - 15:40	12: OP06: The influence of different prednisolone tapering algorithms on the effectiveness of infliximab in patients with Ulcerative Colitis – A real-world cohort study P. Ovesen, Herlev, Denmark
15:40 - 16:00	13: Can IBD Nurses replace IBD physicians? S. Ben-Horin, Ramat Gan, Israel K. Greveson, London, United Kingdom
16:00 - 17:20	Scientific Session 3: Aiming high with treatment goals in IBD: The modern Icarus A. Dignass, Frankfurt, Germany S. Restellini, Geneva, Switzerland
16:00 - 16:20	14: Disease clearance in UC: Is it possible and how do we achieve it? S. Danese, Milan, Italy
16:20 - 16:40	15: Transmural vs. endoscopic healing in CD: What is the ultimate goal? T. Kucharzik, Lüneburg, Germany C. Maaser, Lüneburg, Germany
16:40 - 16:50	16: OP07: Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial S. Schreiber, Kiel, Germany

Scientific programme day by day

16:50 - 17:00	17: OP08: The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 U-ACHIEVE maintenance results S. Danese, Milan, Italy
17:00 - 17:20	18: Molecular healing: Looking into the future R. Atreya, Erlangen, Germany
17:30 - 18:30	Digital Oral Presentations (Sessions 1-5) see page 13
18:45 - 19:45	Industry Sponsored Satellite Symposia 2a, 2b, 2c, 2d, 2e

OP = Oral presentation – Best abstracts

Friday, February 18, 2022

Scientific programme day by day (as per February 9, 2022)

07:15 - 08:15	Industry Sponsored Morning Satellite Symposia 3b, 3d
08:30 - 10:30	Scientific Session 4: Modern monitoring of IBD K. Karmiris, Heraklion, Greece H. Yanai, Tel Aviv, Israel
08:30 - 08:50	19: What is the optimal timing and method for monitoring? E. Louis, Liège, Belgium
08:50 - 09:00	20: OP09: Proactive therapeutic drug monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study K. Jørgensen, Oslo, Norway
09:00 - 09:10	21: OP10: Comparative efficacy of biologics for endoscopic healing of the ileum and colon in Crohn's Disease N. Narula, Hamilton, Canada
09:10 - 09:20	22: OP11: Expanded genome-wide association study of Inflammatory Bowel Disease identifies 174 novel loci and directly implicates new genes in disease susceptibility L. Fachal, Hinxton, United Kingdom
09:20 - 09:40	23: ECCO Guidelines on Ulcerative Colitis – Medical and Surgical Treatment Y. Panis, Clichy, France T. Raine, Cambridge, United Kingdom
09:40 - 09:50	24: OP12: Segmental vs Total Colectomy for Crohn's Disease of the colon in the biologic era. Results from the SCOTCH international, multicentric study G. Pellino, Naples, Italy
09:50 - 10:00	25: OP13: Modified 2-stage vs. 3-stage ileal pouch-anal anastomosis result in equivalent long-term functional outcomes and pouch survival: A matched-pair analysis S. Holubar, Cleveland, United States
10:00 - 10:10	26: OP14: Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing M. Krzak, Hinxton, United Kingdom
10:10 - 10:30	27: What is the optimal way of diagnosing and monitoring fibrosis? K. Gecse, Amsterdam, The Netherlands P. Paolantonio, Rome, Italy
10:30 - 11:00	Break

OP = Oral presentation – Best abstracts

Scientific programme day by day

11:00 - 12:30	Scientific Session 5: Histology in IBD: What the gastroenterologist should know D. Duricova, Prague, Czech Republic M. Svrcek, Paris, France
11:00 - 11:20	28: AI and histology A. Pollett, Toronto, Canada
11:20 - 11:30	29: OP15: A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis T. Parigi, Birmingham, United Kingdom
11:30 - 11:50	30: Fibrosis in CD vs. UC F. Ungaro, Milan, Italy
11:50 - 12:00	31: OP16: The first Virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis M. Iacucci, Birmingham, United Kingdom
12:00 - 12:10	32: OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study) B. Bokemeyer, Minden, Germany
12:10 - 12:30	33: What is the best histologic index? L. Biedermann, Zurich, Switzerland A. Walsh, Oxford, United Kingdom
12:30 - 13:30	Break
12:40 - 13:20	Industry Sponsored Lunch Satellite Symposia LS1, LS2, LS3, LS4, LS5
13:30 - 15:00	Scientific Session 6: Do we see light at the end of the fistula track? G. Pellino, Aversa, Italy G. Rogler, Zurich, Switzerland
13:30 - 13:50	34: Limitations of medical approaches W. Bemelman, Amsterdam, The Netherlands
13:50 - 14:00	35: OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn's Disease: Results from the phase 2 DIVERGENCE 2 study W. Reinisch, Vienna, Austria
14:00 - 14:20	36: Positioning medical options A. Armuzzi, Rome, Italy
14:20 - 14:30	37: OP19: Classifying perianal fistulising Crohn's Disease: An expert-consensus to guide decision-making in daily practice and clinical trials J. Geldof, Ghent, Belgium
14:30 - 14:40	38: OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix L. Constable, London, United Kingdom

OP = Oral presentation – Best abstracts

14:40 - 15:00	39: Is endoscopic treatment really an option? P. Kotze, Curitiba, Brazil
15:00 - 15:30	Break
EITHER:	
15:30 - 16:14	Scientific Session 7: COVID and non-COVID infections T. Kucharzik, Lüneburg, Germany V. Pittet, Lausanne, Switzerland
15:30 - 15:44	40: Lessons from the COVID pandemic for IBD management S. Ng, Hong Kong, China
15:44 - 15:54	41: OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab J. Alexander, London, United Kingdom
15:54 - 16:04	42: OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients S. Lin, Exeter, United Kingdom
16:04 - 16:14	43: Infections with biologics and small molecules: Impact on drug positioning P. Ellul, Sliema, Malta
16:14 - 17:14	Scientific Session 8: IBD Horizons M. Samaan, London, United Kingdom S. Schreiber, Kiel, Germany
16:14 - 16:24	44: OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12 A. Dignass, Frankfurt, Germany
16:24 - 16:34	45: OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study S. Danese, Milan, Italy
16:34 - 16:44	46: OP25: Patients with moderate to severe Crohn's Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials M. Ferrante, Leuven, Belgium
16:44 - 16:54	47: OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study G. D'Haens, Amsterdam, The Netherlands

OP = Oral presentation – Best abstracts

Scientific programme day by day

16:54 - 17:04	48: OP27: A Phase 1 Study evaluating the bioequivalence of the proposed commercial and clinical formulations of Etrasimod 2mg, and the effect of food on the pharmacokinetics of the proposed commercial formulation in healthy volunteers C. Lee, San Diego, United States
17:04 - 17:14	49: OP28: A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD) M. Truyens, Ghent, Belgium
OR:	
15:30 - 17:10	Scientific Session 9: Basic Science: From basic science to practical approach I. Dotan, Petah Tikva, Israel M. Scharl, Zurich, Switzerland
15:30 - 15:50	50: Predicting response to medications in IBD – from basic science to practical approach Y. Chowers, Haifa, Israel
15:50 - 16:00	51: OP29: Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn's Disease patients V. Joustra, Amsterdam, The Netherlands
16:00 - 16:10	52: OP30: Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE B. Verstockt, Leuven, Belgium
16:10 - 16:30	53: What is the real impact of diet on organ biology outside microbiome? T. Adolph, Innsbruck, Austria
16:30 - 16:40	54: OP31: Dietary and Multi-Omic characterization of new onset treatment naïve Crohn Disease identifies factors that may contribute to disease pathogenesis Y. Haberman Ziv, Ramat Gan, Israel
16:40 - 16:50	55: OP32: Pyroptosis inhibition prevents the cytotoxicity induced by IL-17 without impairing its beneficial effects S. Hong, Seoul, South Korea
16:50 - 17:10	56: Will the revolution of OMICs translate into a better care? K. Aden, Kiel, Germany
17:25 - 18:25	Digital Oral Presentations (Sessions 6-10) see page 13
18:40 - 19:40	Industry Sponsored Satellite Symposia 4a, 4b, 4c, 4d, 4e

OP = Oral presentation – Best abstracts

Saturday, February 19, 2022

Scientific programme day by day (as per February 9, 2022)

08:30 - 10:20	Scientific Session 10: Beyond the gut A. De Vries, Rotterdam, The Netherlands Z. Zelinkova, Bratislava, Slovakia
08:30 - 08:50	57: What can we learn from rheumatology in terms of sequencing therapies M. D'Agostino, Rome, Italy D. Aletaha, Vienna, Austria
08:50 - 09:00	58: OP33: Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme J. Colombel, New York, United States
09:00 - 09:20	59: Impact of EIMs on drug choice P. Lakatos, Budapest, Hungary; Montreal, Canada
09:20 - 09:30	60: OP34: Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis R. Panaccione, Calgary, Canada
09:30 - 09:50	61: ECCO Guidelines on Sexuality, Fertility, Pregnancy and Lactation J. Torres, Lisbon, Portugal J. van der Woude, Rotterdam, The Netherlands
09:50 - 10:00	62: OP35: Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based study M. Fumery, Amiens, France
10:00 - 10:10	63: OP36: Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study B. Sands, New York, United States
10:10 - 10:20	64: OP37: Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells L. Mathew, London, United Kingdom
10:20 - 10:50	Break

Scientific programme day by day

10:50 - 12:20	Scientific Session 11: Minimising malignancy risks: Clinical cases C. Af Björkesten, Helsinki, Finland P. Irving, London, United Kingdom
10:50 - 11:10	65: Small bowel dysplasia/malignancy: Proactive or reactive? P. Juillerat, Bern, Switzerland
11:10 - 11:20	66: OP38: Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials R. Panaccione, Calgary, Canada
11:20 - 11:40	67: Skin cancer in IBD: Practical advice from a dermatologist A. Van Laethem, Leuven, Belgium
11:40 - 11:50	68: OP39: Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
11:50 - 12:00	69: OP40: Efficacy of risankizumab induction and maintenance therapy by baseline Crohn's Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies P. Bossuyt, Bonheiden, Belgium
12:00 - 12:20	70: ECCO Guidelines on IBD and Malignancies H. Gordon, London, United Kingdom T. Raine, Cambridge, United Kingdom
12:20 - 13:15	Scientific Session 12: ECCO Lecture L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France B. Siegmund, Berlin, Germany
12:20 - 12:50	71: A European IBD voyage S. Vermeire, Leuven, Belgium
12:50 - 13:05	72: Awards and Closing remarks
13:05 - 13:15	The ECCO Film

OP = Oral presentation – Best abstracts

Digital oral presentations (DOP)

Thursday, February 17, 2022

17:30 - 18:30	Digital Oral Presentations Sessions 1-5
Digital Oral Presentation Session 1	The Arctic: Epidemiology & Genetics V. Pittet, Lausanne, Switzerland J. Guedelha Sabino, Leuven, Belgium
Digital Oral Presentation Session 2	The Pacific: Imaging in IBD M. Iacucci, Birmingham, United Kingdom C. Maaser, Lüneburg, Germany
Digital Oral Presentation Session 3	The Indian: IBD & COVID-19 H. Gordon, London, United Kingdom T. Kucharzik, Lüneburg, Germany
Digital Oral Presentation Session 4	The Atlantic: Surgery & Outcome G. Pellino, Naples, Italy P. Gionchetti, Bologna, Italy
Digital Oral Presentation Session 5	The Southern: Small molecules in IBD I. Dotan, Petah Tikva, Israel B. Verstockt, Leuven, Belgium

Friday, February 18, 2022

17:25 - 18:25	Digital Oral Presentations Sessions 6-10
Digital Oral Presentation Session 6	The Arctic: IBD Basic Science C. Hedin, Stockholm, Sweden T. Raine, Cambridge, United Kingdom
Digital Oral Presentation Session 7	The Pacific: Histology, artificial intelligence & more F. Rosini, Bologna, Italy S. Sebastian, Hull, United Kingdom
Digital Oral Presentation Session 8	The Indian: Anti-TNF & Paediatrics J. Burisch, Hvidovre, Denmark L. de Ridder, Rotterdam, The Netherlands
Digital Oral Presentation Session 9	The Atlantic: Comparative effectiveness & Biomarkers M. Chaparro, Madrid, Spain M. Samaan, London, United Kingdom
Digital Oral Presentation Session 10	The Southern: Blocking p19 or p40 D. Bettenworth, Münster, Germany K. Gecse, Amsterdam, The Netherlands

20th IBD Intensive Course for Trainees

Date: Wednesday, February 16, 2022
Time: 08:00-17:20
Organisation: EduCom
Recommended for: Junior gastroenterologists
Registration: ECCO Membership 2022 required
 Upon invitation only
CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form

Wednesday, February 16, 2022

(as per February 9, 2022)

08:00 - 08:15	Arrival & download of ECCO IBD App
08:15 - 08:20	1: Welcome & Introduction from the course director F. Magro, Porto, Portugal L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France H. Yanai, Petah Tikva, Israel
08:20 - 10:20	Session 1: Introduction and case-based management on conventional IBD therapies Lead discussant: J. Lindsay, London, United Kingdom
08:20 - 09:00	2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics I. Dotan, Petah Tikva, Israel
09:00 - 09:20	3: 5-ASA compounds K. Karmiris, Heraklion, Greece
09:20 - 09:40	4: Thiopurines J. Torres, Loures, Portugal
09:40 - 10:00	5: Methotrexate P. Juillerat, Bern, Switzerland
10:00 - 10:20	6: Steroids H. Yanai, Petah Tikva, Israel
10:20 - 10:40	Break
10:40 - 12:30	Session 2: Case-based management of conventional IBD therapies Lead discussant: B. Siegmund, Berlin, Germany
10:40 - 11:10	7: Anti-TNF agents and TDM P. Michetti, Lausanne, Switzerland
11:10 - 11:30	8: Anti-integrins J. Lindsay, London, United Kingdom
11:30 - 11:50	9: Anti-IL 12/23 M. Ferrante, Leuven, Belgium
11:50 - 12:10	10: JAK inhibitors S. Danese, Milan, Italy
12:10 - 12:30	11: Medication in the pipeline L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France

12:30 - 14:00 Break	
14:00 - 14:30	12: Positioning therapeutic strategies in IBD S. Ben-Horin, Ramat Gan, Israel
14:30 - 15:30	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 1 Lead discussant: H. Yanai, Petah Tikva, Israel
14:30 - 15:30	13a: Pregnancy I. Dotan, Petah Tikva, Israel J. van der Woude, Rotterdam, The Netherlands 13b: Extraintestinal manifestations K. Karmiris, Heraklion, Greece P. Lakatos, Budapest, Hungary; Montreal, Canada 13c: When and how to start biologics? G. Mantzaris, Athens, Greece B. Siegmund, Berlin, Germany
15:30 - 15:50 Break	
15:50 - 17:20	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 2
15:50 - 17:10	13d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 13e: Therapeutic Drug Monitoring F. Baert, Roeselare, Belgium P. Juillerat, Bern, Switzerland 13f: Exit strategy M. Ferrante, Leuven, Belgium J. Torres, Loures, Portugal 13g: Therapeutic Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel
17:10 - 17:20	14: Summary and conclusions H. Yanai, Petah Tikva, Israel

13th N-ECCO School

Date: Wednesday, February 16, 2022
Time: 08:30-16:45
Organisation: N-ECCO
Recommended for: IBD Nurses, Dietitians
Registration: IBD Nurse/Affiliate Membership 2022 required
 Upon invitation only
CME accreditation: N/A

Wednesday, February 16, 2022

(as per February 9, 2022)

08:30 - 08:45	1: Welcome & Introduction M. Ganon, Jerusalem, Israel
08:45 - 12:15	Session 1: Diagnosis and assessment M. Campmans-Kuijpers, Groningen, The Netherlands M. Ganon, Jerusalem, Israel
08:45 - 09:30	2: Diagnosis, anatomy and physiology in IBD M. Ferrante, Leuven, Belgium
09:30 - 10:00	3: Psychosocial implications of living with IBD W. Czuber-Dochan, London, United Kingdom
10:00 - 10:30	4: Nutritional assessment in IBD L. Godny, Petah Tikva, Israel
10:30 - 10:45	Break
10:45 - 11:15	5: Surgery in IBD M. Adamina, Winterthur, Switzerland
11:15 - 11:45	6: Medical treatment J. Burisch, Hvidovre, Denmark
11:45 - 12:15	7: Adherence S. Jäghult, Stockholm, Sweden
13:45 - 15:15	Session 2: Case studies – Disease management P. Hartmann, Minden, Germany A. Ibarra, London, United Kingdom
13:45 - 14:30	8: UC Management M. Samaan, London, United Kingdom
14:30 - 15:15	9: CD Management E. Langholz, Hellerup, Denmark
15:15 - 15:30	Break
15:30 - 16:45	Session 3: Multidisciplinary management in IBD P. Hartmann, Minden, Germany E. Wine, Edmonton, Canada
15:30 - 16:00	10: Nutritional management in IBD D. O'Hanlon, London, United Kingdom
16:00 - 16:30	11: Nursing roles in IBD management A. Ibarra, London, United Kingdom
16:30 - 16:45	12: Closing remarks M. Ganon, Jerusalem, Israel

6th Basic ECCO: EduCational COurse for Industry

Date: Wednesday, February 16, 2022
Time: 10:00-16:40
Organisation: ClinCom
Recommended for: Corporate Members & Non-Corporate Members
Registration: ECCO Membership 2022 NOT required
CME accreditation: N/A

Wednesday, February 16, 2022

(as per February 9, 2022)

10:00 - 10:05	1: Welcome P. Bossuyt, Bonheiden, Belgium
10:05 - 12:00	Session 1: IBD from symptoms to diagnosis L. Beaugerie, Paris, France
10:05 - 10:40	2: First presentation at the clinic N. Teix, Innsbruck, Austria H. Tilg, Innsbruck, Austria
10:40 - 11:10	3: Initial work up after diagnosis of IBD S. Jäghult, Stockholm, Sweden C. Hedin, Stockholm, Sweden
11:10 - 11:45	4: IBD is team work W. Bemelman, Amsterdam, The Netherlands M. De Jong, Amsterdam, The Netherlands G. D'Haens, Amsterdam, The Netherlands
11:45 - 12:00	5: Question time
12:00 - 13:00	Break
13:00 - 14:40	Session 2: IBD from diagnosis to treatment S. Sebastian, Hull, United Kingdom
13:00 - 13:15	6: First think about the strategy! P. Bossuyt, Bonheiden, Belgium
13:15 - 13:30	7: "Older" medication: Still useful? U. Kopylov, Tel Aviv, Israel
13:30 - 13:45	8: "Mainstream" biologicals when to use? J. Colombel, New York, United States
13:45 - 14:00	9: "New" kids on the block B. Siegmund, Berlin, Germany
14:00 - 14:15	10: "Special" treatments H. Sokol, Paris, France
14:15 - 14:30	11: Safety after all L. Beaugerie, Paris, France
14:30 - 14:40	12: Question time
14:40 - 15:00	Break

6th Basic ECCO: EduCational COurse for Industry

15:00 - 16:15	<i>Session 3: IBD from the outpatient clinic to the operation theater</i> U. Kopylov, Tel Aviv, Israel
15:00 - 15:20	<i>13: Problems around the anus</i> S. Danese, Milan, Italy A. Spinelli, Milan, Italy
15:20 - 15:40	<i>14: Surgical intervention in CD: When, how and what afterwards</i> W. Bemelman, Amsterdam, The Netherlands K. Gecse, Amsterdam, The Netherlands
15:40 - 16:00	<i>15: Surgical intervention in UC: When, how and what afterwards</i> Y. Panis, Clichy, France L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
16:00 - 16:15	<i>16: Question time</i>
16:15 - 16:40	<i>Session 4: IBD what have we learnt? What can we learn</i> K. Gecse, Amsterdam, The Netherlands
16:15 - 16:35	<i>17: Gaps in IBD care and research</i> P. Bossuyt, Bonheiden, Belgium
16:35 - 16:40	<i>18: Closing remarks</i> K. Gecse, Amsterdam, The Netherlands

8th Y-ECCO Basic Science Workshop

Date: Wednesday, February 16, 2022
Time: 12:30-16:30
Organisation: Y-ECCO
Recommended for: Basic scientists, Physicians, Paediatricians, Surgeons, IBD Nurses
 Other professions are kindly invited to register.
Registration: ECCO Membership 2022 required
 Online registration
CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form

Wednesday, February 16, 2022

(as per February 9, 2022)

12:30 - 12:35	1: Introduction J. Burisch, Hvidovre, Denmark
12:35 - 13:50	Session 1: New Challenges in Immunology N. Björkström, Stockholm, Sweden C. Hedin, Stockholm, Sweden
12:35 - 13:05	2: New Challenges in Immunology N. Björkström, Stockholm, Sweden
13:05 - 13:20	3: Abstract presentation: Myeloid and lymphoid cell abnormalities persist in the intestinal mucosa of patients who recover from COVID-19 infection H. Meringer, New York, United States
13:20 - 13:35	4: Abstract presentation: Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: report from the ICARUS-IBD Consortium J. Wellens, Leuven, Belgium
13:35 - 13:50	5: Abstract presentation: Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease B. Rodger, London, United Kingdom
13:50 - 14:15	Meet the speakers break

14:15 - 15:30	Session 2: Predicting the Future P. Rosenstiel, Kiel, Germany B. Verstockt, Leuven, Belgium
14:15 - 14:45	6: Predicting the Future P. Rosenstiel, Kiel, Germany
14:45 - 15:00	7: Abstract presentation: In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencing A. Bourgonje, Groningen, The Netherlands
15:00 - 15:15	8: Abstract presentation: Intestinal lymphoepithelial interactions in Crohn's disease: modeling alphaE-beta7 and NKG2D blockade N. Hammoudi, Paris, France
15:15 - 15:30	9: Abstract presentation: Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment N. Karmi, Groningen, The Netherlands
15:30 - 16:30	Session 3: Getting Published! J. Burisch, Hvidovre, Denmark L. Egan, Galway, Ireland
15:30 - 15:45	10: Getting Published! L. Egan, Galway, Ireland
15:45 - 16:00	11: Understanding the mechanisms of anti-TNF treatment failure in patients with Crohn's Disease: A proteomic analysis of the PANTS cohort N. Chanchlani, Exeter, United Kingdom
16:00 - 16:15	12: CCR6 blockade as novel therapeutic strategy against Inflammatory Bowel Disease S. Bertoni, Parma, Italy
16:15 - 16:30	13: Closing remarks and Y-ECCO best abstract awards J. Burisch, Hvidovre, Denmark

6th EpiCom Workshop

Date: Wednesday, February 16, 2022
Time: 13:30-16:40
Organisation: EpiCom
Target audience: Physicians, Surgeons, Paediatricians, IBD Nurses
 Other professions are kindly invited to register.
Registration: ECCO Membership 2022 required
 Online registration
CME accreditation: 3 CME Credits; prerequisite: completion of the
 online evaluation form

Wednesday, February 16, 2022

(as per February 9, 2022)

13:30 - 13:40	1: Welcome & Introduction N. Arebi, Harrow, United Kingdom
13:40 - 15:20	Session 1: Overview of prognostic factors and outcomes in IBD B. Alizadeh, Groningen, The Netherlands R. Misra, London, United Kingdom
13:40 - 14:10	2: Core outcomes of relevance to prognosis (Position Statement) N. Arebi, Harrow, United Kingdom V. Pittet, Lausanne, Switzerland
14:10 - 14:30	3: Disease risk factors as prognostic tools F. Magro, Porto, Portugal
14:30 - 15:00	4: Prognostic factors for therapy (Drug & Surgery therapy) J. Kirchgesner, Paris, France S. Restellini, Geneva, Switzerland
15:00 - 15:20	5: Panel Discussion with Q&A N. Arebi, Harrow, United Kingdom J. Kirchgesner, Paris, France F. Magro, Porto, Portugal V. Pittet, Lausanne, Switzerland S. Restellini, Geneva, Switzerland
15:20 - 15:40	Break
15:40 - 16:40	Session 2: Application of prognostic factors current practice and future promise for precision medicine N. Arebi, London, United Kingdom
15:40 - 16:10	6: The implementation of prognostic factors to manage and modify outcomes - case based discussion J. Kirchgesner, Paris, France S. Restellini, Geneva, Switzerland
16:10 - 16:30	7: Precision Medicine to improve outcomes – dream or reality S. Ng, Hong Kong, China
16:30 - 16:40	8: Take home message & farewell N. Arebi, Harrow, United Kingdom

7th N-ECCO Research Forum

Date:	Wednesday, February 16, 2022
Time:	14:00-17:30
Organisation:	N-ECCO
Target audience:	IBD Nurses and Allied health professionals Other professions are kindly invited to register.
Registration:	ECCO Membership 2022 required Online registration
CME accreditation:	N/A

Wednesday, February 16, 2022*(as per February 9, 2022)*

14:00 - 14:10	1: Welcome & Introduction W. Czuber-Dochan, London, United Kingdom
14:10 - 15:10	Session 1: Presentation by the previous N-ECCO Research Grant winners W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
14:10 - 14:30	2: Research Award Outcomes 2020 S. Fourie, Oxford, United Kingdom K. Pihl Lesnovska, Linköping, Sweden
14:30 - 14:50	3: Research Award Presenters 2021 M. van Gaalen, Rotterdam, The Netherlands M. Van Pieterse, Rotterdam, The Netherlands
14:50 - 15:10	4: Research Award Presenter 2022 R. Comoretto, Torino, Italy
15:10 - 16:00	Session 2: Your journey from research questions to the conference presentation W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
15:10 - 15:25	5: How to prepare the research question? S. Fourie, Oxford, United Kingdom
15:25 - 15:40	6: How to conduct the data collection? W. Czuber-Dochan, London, United Kingdom
15:40 - 16:00	7: Abstract presentation and preparation S. Jäghult, Stockholm, Sweden
16:00 - 16:30	Break
16:30 - 17:30	Session 3: Research projects planning W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
16:30 - 17:20	8: Research application preparation in practice W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
17:20 - 17:30	10: Closing remarks W. Czuber-Dochan, London, United Kingdom

2nd ECCO Postgraduate Course in IBD

Date: Thursday, February 17, 2022
Time: 07:30-12:05
Organisation: EduCom
Recommended for: Experienced Gastroenterologists with interest in IBD
 Other professions are kindly invited to register
Registration: ECCO Membership 2022 required
 Online registration
CME accreditation: 4 CME Credits; prerequisite: completion of the online evaluation form

Thursday, February 17, 2022

(as per February 9, 2022)

07:30 - 07:40	1: Introduction F. Magro, Porto, Portugal L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France H. Yanai, Petah Tikva, Israel
07:40 - 09:45	Session 1: Prepare yourself with IBD Experts K. Karmiris, Heraklion, Greece F. Magro, Porto, Portugal
07:40 - 08:00	2: How important is IBD? J. van der Woude, Rotterdam, The Netherlands
08:00 - 08:20	3: How to diagnose and evaluate a new IBD case? L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
08:20 - 08:55	4: How to optimally use conventional drugs? S. Ben-Horin, Ramat Gan, Israel
08:55 - 09:30	5: How to place new biologics and small molecules? S. Danese, Milan, Italy
09:30 - 09:45	6: How to place surgery in IBD? P. Kotze, Curitiba, Brazil
09:45 - 10:00	Break

10:00 - 12:05	<i>Session 2: Case-based discussion with IBD Experts</i> P. Juillerat, Bern, Switzerland H. Yanai, Petah Tikva, Israel
10:00 - 10:45	<i>CD cases presentation</i> T. Lobaton Ortega, Gent, Belgium
10:45 - 11:00	<i>Discussion</i> L. Beaugerie, Paris, France T. Lobaton Ortega, Gent, Belgium F. Magro Dias, Porto, Portugal H. Yanai, Tel Aviv, Israel
11:00 - 11:45	<i>UC cases presentation: newly diagnosed</i> S. Restellini, Geneva, Switzerland
11:45 - 12:00	<i>Discussion</i> G. Doherty, Dublin, Ireland P. Juillerat, Bern, Switzerland S. Restellini, Geneva, Switzerland B. Siegmund, Berlin, Germany
12:00 - 12:05	<i>11: Conclusion and remarks</i> F. Magro, Porto, Portugal L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France H. Yanai, Petah Tikva, Israel

11th S-ECCO IBD Masterclass in collaboration with ESCP

Date: Thursday, February 17, 2022
Time: 07:30-17:00
Organisation: S-ECCO in collaboration with ESCP
Recommended for: Surgeons, Physicians, IBD Nurses
 Other professions are kindly invited to register



Registration: ECCO Membership 2022 required
 Online registration

CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form

Thursday, February 17, 2022

(as per February 9, 2022)

07:30 - 07:40	1: Welcome M. Adamina, Winterthur, Switzerland
07:40 - 09:30	Session 1: Less is more – decreasing care burden M. Agrawal, New York, United States S. Holubar, Cleveland, United States
07:40 - 08:25	Debate 1: Crohn's Disease
07:40 - 07:55	2: Surgery first or...? P. Juillerat, Bern, Switzerland
07:55 - 08:10	3: CD surgery beyond plain resection T. Kalman, Linköping, Sweden
08:10 - 08:25	4: Discussion
08:25 - 09:10	Debate 2: Ulcerative Colitis
08:25 - 08:40	5: Tailored medical therapy in UC E. Langholz, Hellerup, Denmark
08:40 - 08:55	6: Tailored approaches in UC surgery P. Kotze, Curitiba, Brazil
08:55 - 09:10	7: Discussion
09:10 - 09:30	8: Thinking out of the box – evolutions and revolutions in IBD W. Bemelman, Amsterdam, The Netherlands
09:30 - 10:00	Break

11th S-ECCO IBD Masterclass in collaboration with ESCP

10:00 - 11:30	Session 2: Hyperbaric oxygen C. Buskens, Amsterdam, The Netherlands P. Myrelid, Linköping, Sweden
10:00 - 10:15	9: Crohn's Disease C. Lansdorp, Amsterdam, The Netherlands
10:15 - 10:30	10: Colitis and pouchitis S. Holubar, Cleveland, United States
10:30 - 11:00	The scientific surgeon – Free Papers
10:30 - 10:40	11: Abstract presentation: Functional outcomes of transanal versus transabdominal proctectomy with ileal pouch-anal anastomosis in Ulcerative Colitis. A comparative study. G. Bislenghi, Leuven, Belgium
10:40 - 10:50	12: Abstract presentation: Long-term outcomes of Crohn's perianal fistulas treatment: anti-TNF with surgical closure versus anti-TNF alone (PISA-II) – a patient preference RCT E. Meima-van Praag, Amsterdam, The Netherlands
10:50 - 11:00	13: Abstract presentation: Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study) M. Chaparro, Madrid, Spain
11:00 - 11:30	The scientific surgeon – Trial updates
11:00 - 11:10	14: The REC trial or RCT Kono-S interim analysis A. Spinelli, Milan, Italy
11:10 - 11:20	15: Appendectomy in UC (COSTA, ACCURE, long-term PASSION) W. Bemelman, Amsterdam, The Netherlands
11:20 - 11:30	16: Optimising reporting in surgery, endoscopy and histopathology M. Iacucci, Birmingham, United Kingdom
11:45 - 12:45	Break
11:45 - 12:45	Lunch Satellite Symposium
13:00 - 15:00	Session 3: Stenosis and anastomosis in Crohn's Disease P. Kotze, Curitiba, Brazil C. Vaizey, Harrow, United Kingdom
13:00 - 13:15	17: Time-tested approaches J. Warusawitarne, Harrow, United Kingdom
13:15 - 13:30	18: Ileocecal over the inlet A. D'Hoore, Leuven, Belgium
13:30 - 13:45	19: Kono-S anastomosis S. Brown, Fitzroy, Australia
13:45 - 13:55	20: Discussion

13:55 - 14:25	<i>Surgical technique session: Cancer in IBD</i>
13:55 - 14:10	21: CD and UC: Differences and clinical implications A. Armuzzi, Rome, Italy
14:10 - 14:25	22: IBD and cancer – Medical or surgical therapy? M. Agrawal, New York United States
14:25 - 15:00	<i>Surgical technique session: Cancer in IBD – surgical strategy</i>
14:25 - 14:40	23: Surgical strategy in CD M. Adamina, Winterthur, Switzerland
14:40 - 14:55	24: Surgical strategy in UC C. Buskens, Amsterdam, The Netherlands
14:55 - 15:00	25: Discussion
15:00 - 15:30	<i>Break</i>
15:30 - 16:15	<i>Session 4: Failure Session</i> A. Armuzzi Rome, Italy S. Brown, Fitzroy, Australia
15:30 - 15:45	26: Surgical complications P. Myrelid, Linköping, Sweden
15:45 - 16:00	27: Short bowel C. Vaizey, Harrow, United Kingdom
16:00 - 16:15	28: Pouch failure A. Spinelli, Milan, Italy
16:15 - 16:45	<i>Session 5: Consultants' corner on challenging cases</i> A. D'Hoore, Leuven, Belgium P. Myrelid, Linköping, Sweden A. Spinelli, Milan, Italy C. Vaizey, Harrow, United Kingdom
16:15 - 16:30	29: First clinical case A. D'Hoore, Leuven, Belgium
16:30 - 16:45	30: Second clinical case C. Vaizey, Harrow, United Kingdom
16:45 - 17:00	30: Closing remarks C. Buskens, Amsterdam, The Netherlands

9th ECCO Ultrasound Workshop – Advanced in collaboration with ESGAR



Date: Thursday, February 17, 2022
Time: 07:45-11:45
Organisation: EduCom in collaboration with ESGAR
Recommended for: Physicians, Radiologists, Surgeons, Paediatricians
Other professions are kindly invited to register
Registration: ECCO Membership 2022 required
Online registration
CME accreditation: 3 CME Credits; prerequisite: completion of the
online evaluation form

Thursday, February 17, 2022
(as per February 9, 2022)

07:45 - 07:50	1: Welcome & Introduction C. Maaser, Lüneburg, Germany P. Paolantonio, Rome, Italy
07:50 - 09:35	Session 1: Assessment of IBD G. Maconi, Milan, Italy C. Maaser, Lüneburg, Germany
07:50 - 08:05	2: Scoring activity and response in CD and UC R. Wilkens, Copenhagen, Denmark
08:05 - 08:25	3: Interactive video presentation 1 R. Wilkens, Copenhagen, Denmark
08:25 - 08:40	4: Standardized reporting and documentation T. Kucharzik, Lüneburg, Germany
08:40 - 09:00	5: Interactive video presentation 2 T. Kucharzik, Lüneburg, Germany
09:00 - 09:15	6: Detecting complications in UC K. Gecse, Amsterdam, The Netherlands
09:15 - 09:35	7: Interactive video presentation 3 K. Gecse, Amsterdam, The Netherlands
09:35 - 10:00	Break

Session 2: IUS special situations	
10:00 - 11:30	T. Kucharzik, Lüneburg, Germany J. Torres, Loures, Portugal
10:10 - 10:15	8: Detecting complication in CD H. Al Frahan, Kuwait City, Kuwait
10:15 - 10:30	9: Interactive video presentation 4 H. Al Frahan, Kuwait City, Kuwait
10:30 - 10:45	10: Tips and Tricks on how to optimize your image G. Maconi, Milan, Italy
10:45 - 11:10	11: Interactive video presentation 5 G. Maconi, Milan, Italy
11:10 - 11:30	12: IUS trials in IBD – What can we learn from the rheumatologists experience? M. D'Agostino, Rome, Italy
11:30 - 11:45	14: Post course test, summary and closing remarks C. Maaser, Lüneburg, Germany P. Paolantonio, Rome, Italy

8th ClinCom Workshop

Date:	Thursday, February 17, 2022
Time:	08:00-11:40
Organisation:	ClinCom
Recommended for:	Physicians, Surgeons, Paediatricians, Clinical researchers, Industry Other professions are kindly invited to register
Registration:	ECCO Membership 2022 required Online registration
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form

Thursday, February 17, 2022*(as per February 9, 2022)*

08:00 - 08:05	1: Welcome & Introduction K. Gecse, Amsterdam, The Netherlands
08:05 - 09:45	Session 1: Moving IBD care from clinic to home P. Bossuyt, Bonheiden, Belgium
08:05 - 08:20	2: Patient driven monitoring of symptoms G. Fiorino, Milan, Italy
08:20 - 08:40	3: Remote monitoring of biomarkers P. van Rheeën, Groningen, The Netherlands
08:40 - 09:00	4: Wearable devices in IBD – Is this the future? U. Kopylov, Tel Aviv, Israel
09:00 - 09:20	5: Remote monitoring of IBD patients – Challenges and future perspectives N. Teix, Innsbruck, Austria H. Tilg, Innsbruck, Austria
09:20 - 09:45	6: Impact of COVID-19 on clinical research in IBD T. Raine, Cambridge, United Kingdom
09:45 - 10:15	Break
10:15 - 11:40	Session 2: Keep the remission going U. Kopylov, Tel Aviv, Israel
10:15 - 10:35	7: Non-pharmacological strategies: Ready for primetime? J. Lindsay, London, United Kingdom
10:35 - 10:55	8: Proactive TDM: Feasible? Reasonable? K. Papamichail, Boston, United States
10:55 - 11:15	9: De-escalation and elective mode switching when? How? E. Louis, Liege, Belgium
11:15 - 11:30	10: Remission: How deep? S. Sebastian, Hull, United Kingdom
11:30 - 11:40	11: Summary & closing remarks U. Kopylov, Tel Aviv, Israel
12:00 - 13:00	Lunch Satellite Symposium

10th SciCom Workshop:

New horizons in IBD therapy

Date: Thursday, February 17, 2022
Time: 08:45-11:45
Organisation: SciCom
Recommended for: Basic scientists and interested clinicians
 Other professions are kindly invited to register
Registration: ECCO Membership 2022 required
 Online registration
CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form

Thursday, February 17, 2022

(as per February 9, 2022)

08:45 - 10:05	Session 1: Future host and microbial target in IBD K. Papamichail, Boston, United States S. Zeissig, Dresden, Germany
08:45 - 08:50	1: Welcome & Introduction S. Zeissig, Dresden, Germany
08:50 - 09:10	2: Limitations of current IBD treatments and future opportunities M. Ferrante, Leuven, Belgium
09:10 - 09:35	3: Host and microbial metabolites as therapeutic targets in IBD K. Aden, Kiel, Germany
09:35 - 10:05	4: Adipose tissue – from bench to bedside Y. Panis, Clichy, France B. Siegmund, Berlin, Germany
10:05 - 10:25	Break
10:25 - 11:45	Session 2: Genetics and insight into new IBD targets M. Ferrante, Leuven, Belgium M. Scharl, Zurich, Switzerland
10:25 - 10:50	5: Single cell sequencing and insight into novel therapeutic targets in IBD A. Denadai Souza, Leuven, Belgium
10:50 - 11:15	6: Somatic mutations and their therapeutic implications in IBD T. Raine, Cambridge, United Kingdom
11:15 - 11:40	7: From allogeneic stem cell transplantation to gene editing in the cure of IBD J. Van Limbergen, Amsterdam, The Netherlands
11:40 - 11:45	6: Closing remarks M. Scharl, Zurich, Switzerland

9th P-ECCO Educational Course

Date:	Thursday, February 17, 2022
Time:	09:00-11:00
Organisation:	P-ECCO
Recommended for:	Paediatricians, Physicians, Surgeons Other professions are kindly invited to register
Registration:	ECCO Membership 2022 required Online registration
CME accreditation:	2 CME Credits; prerequisite: completion of the online evaluation form

Thursday, February 17, 2022

(as per February 9, 2022)

09:00 - 11:00	<i>Paediatric IBD, when the going gets tough</i> D. Wilson, Edinburgh, United Kingdom
09:00 - 09:05	<i>1: Welcome</i> D. Wilson, Edinburgh, United Kingdom
09:05 - 09:30	<i>2: Tough biological choices in PIBD; What to choose, when to move, and can we combine?</i> A. Griffiths, Toronto, Canada
09:30 - 09:50	<i>3: When the growing gets tough</i> J. Van Limbergen, Amsterdam, The Netherlands
09:50 - 10:10	<i>4: Little evidence – tough to get it right in PSC</i> M. Aloï, Rome, Italy
10:10 - 10:35	<i>5: Tough and little – dealing with VEOIBD</i> L. de Ridder, Rotterdam, The Netherlands
10:35 - 11:00	<i>6: The tough get going – refractory IBD</i> A. Assa, Petah Tikva, Israel

16th N-ECCO Network Meeting

Date: Thursday, February 17, 2022
Time: 09:00-17:00
Organisation: N-ECCO
Recommended for: IBD Nurses – advanced level
 Other professions are kindly invited to register
Registration: ECCO Membership 2022 required
 Online registration
CME accreditation: N/A

Thursday, February 17, 2022

(as per February 9, 2022)

09:00 - 09:15	1: Welcome & Introduction S. Jäghult, Stockholm, Sweden
09:15 - 10:30	Session 1: Medication and new developments P. Hartmann, Minden, Germany T. Mooslechner, Vienna, Austria
09:15 - 09:40	2: New drugs and "old buddies in new bodies" J. Lindsay, London, United Kingdom
09:40 - 10:05	3: It is all about the delivery: IBD medications in pregnancy J. van der Woude, Rotterdam, The Netherlands
10:05 - 10:30	4: Combination of biologic therapies B. Verstockt, Leuven, Belgium
10:30 - 11:00	Break
11:00 - 12:30	Session 2: Innovation in Research and practice W. Czuber-Dochan, London, United Kingdom A. Ibarra, London, United Kingdom
11:00 - 11:30	5: Challenges and opportunities of Virtual clinics in IBD L. Inganäs, Stockholm, Sweden S. Jäghult, Stockholm, Sweden B. Revital, Petah Tikva, Israel
11:30 - 11:45	6: N01: Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: a multicentre, comparative study E. de Dycker, Rotselaar, Belgium
11:45 - 12:00	7: N02: The importance of the multidisciplinary team (MDT) and its impact on quality of life and medication adherence in patients with Inflammatory Bowel Disease G. Herreras, Sao Paulo, Brazil

12:00 - 12:15	8: N03: Medication adherence in relation to Health-related Quality of Life in patients with Inflammatory Bowel Disease – a cross-sectional study U. Lovén Wickman, Kalmar, Sweden
12:15 - 12:30	9: N04: A systematic review of the impact of Inflammatory Bowel Disease (IBD) on family members P. Thapwong, London, United Kingdom
12:30 - 14:00 Break	
12:45 - 13:45 Lunch Satellite Symposium	
14:00 - 14:45	Session 3: Dietary and psychological care S. Jäghult, Stockholm, Sweden M. Ganon, Jerusalem, Israel
14:00 - 14:20	10: Dietary approaches in IBD L. Godny, Petah Tikva, Israel
14:20 - 14:45	11: Psychological approaches in IBD A. Duff, London, United Kingdom
14:45 - 15:15 Break	
15:15 - 17:00	Session 4: Transition clinic from paediatric to adults IBD W. Czuber-Dochan, London, United Kingdom T. Mooslechner, Vienna, Austria
15:15 - 15:40	12: How the adult's clinic takes care of the young adult J. Lindsay, London, United Kingdom
15:40 - 16:05	13: Everything you need to know about surgery M. Adamina, Winterthur, Switzerland
16:05 - 16:30	14: Relationship, sexuality and family planning S. Fourie, Oxford, United Kingdom
16:30- 17:00	15: Closing remarks S. Jäghult, Stockholm, Sweden

7th H-ECCO IBD Masterclass

Date:	Thursday-Friday, February 17-18, 2022
Time:	Thursday, February 17: 13:15-17:00 Friday, February 18: 08:00-12:00
Organisation:	H-ECCO, endorsed by ESP
Recommended for:	Histopathologists, Clinicians Other professions are kindly invited to register
Registration:	ECCO Membership 2022 required Online registration
CME accreditation:	6 CME Credits; prerequisite: completion of the online evaluation form



Thursday, February 17, 2022

(as per February 9, 2022)

13:15 - 13:20	1: Welcome & Introduction G. De Hertogh, Leuven, Belgium
13:20 - 15:10	Session 1: Basics of IBD Pathology P. Baldin, Woluwe Saint Lambert, Belgium R. Feakins, London, United Kingdom
13:20 - 13:35	2: Histologic markers of chronicity of IBD P. Baldin, Woluwe Saint Lambert, Belgium
13:35 - 13:50	3: Differential Diagnosis of UC and CD in surgical specimens F. Rosini, Bologna, Italy
13:50 - 14:10	4: Differential Diagnosis of UC and CD in endoscopic biopsy specimens: Upper tract UC – does it exist? R. Riddell, Toronto, Canada
14:10 - 14:30	5: Mimickers of IBD G. De Hertogh, Leuven, Belgium
14:30 - 14:55	6: Dysplasia in IBD: The different types and molecular background. Can we agree? M. Svrcek, Paris, France
14:55 - 15:10	7: Standardised histological report in IBD R. Feakins, London, United Kingdom
15:10 - 15:30	Break
15:30- 17:00	Session 2: Secondary Complications of IBD G. De Hertogh, Leuven, Belgium F. Rosini, Bologna, Italy
15:30 - 15:45	8: Dermatological manifestations in IBD F. Bosisio, Leuven, Belgium
15:45 - 16:00	9: Vasculitis in / related to IBD F. Rosini, Bologna, Italy
16:00 - 16:20	10: Pulmonary manifestations of IBD & its differential diagnosis G. De Hertogh, Leuven, Belgium
16:20 - 16:40	11: Neuromuscular complications in IBD M. Tripathi, Cambridge, United Kingdom
16:40 - 17:00	12: Neoplasia in IBD secondary to therapy A. Driessen, Edegem, Belgium

Friday, February 18, 2022

(as per February 9, 2022)

08:00 - 09:45	<i>Session 3: Changing Diagnostics and their Impact on Histopathology</i> P. Bossuyt, Bonheiden, Belgium G. De Hertogh, Leuven, Belgium
08:00 - 08:25	<i>13: Fecal calprotectin can predict histological activity?</i> G. De Hertogh, Leuven, Belgium P. Lakatos, Budapest, Hungary; Montreal, Canada
08:25 - 08:45	<i>14: Radiology in Crohn's Disease</i> J. Panes, Barcelona, Spain J. Rimola, Barcelona, Spain
08:45 - 09:15	<i>15: New endoscopic tools: The PICASSO score, its relation with histology</i> M. Iacucci, Birmingham, United Kingdom
09:15 - 09:45	<i>16: Computer-aided endoscopy for scoring histological remission in UC</i> P. Bossuyt, Bonheiden, Belgium
09:45 - 10:15	<i>Break</i>
10:15 - 12:00	<i>Session 4: Hot topics and challenging case illustrations</i> A. Driessen, Edegem, Belgium F. Rosini, Bologna, Italy
10:15 - 10:35	<i>17: Hot topics in IBD</i> G. De Hertogh, Leuven, Belgium
10:35 - 10:55	<i>18: IBD diagnosis</i> A. Driessen, Edegem, Belgium
10:55 - 11:15	<i>19: IBD differential diagnosis</i> A. Driessen, Edegem, Belgium
11:15 - 11:35	<i>20: Non-neoplastic complications of IBD</i> F. Rosini, Bologna, Italy
11:35 - 11:55	<i>21: Neoplastic complications of IBD</i> P. Baldin, Woluwe Saint Lambert, Belgium
11:55 - 12:00	<i>22: Closing remarks</i> G. De Hertogh, Leuven, Belgium

7th D-ECCO Workshop

Date: Friday, February 18, 2022
Time: 08:15-12:25
Organisation: D-ECCO
Recommended for: Dietitians, IBD Nurses, Physicians
 Other professions are kindly invited to register
Registration: ECCO Membership 2022 required
 Online registration
CME accreditation: 3 CME Credits; prerequisite: completion of the
 online evaluation form

Friday, February 18, 2022

(as per February 9, 2022)

08:15 - 08:20	1: Welcome M. Campmans-Kuijpers, Groningen, The Netherlands
08:20 - 09:30	Session 1: Science – Moving from a causality in IBD M. Campmans-Kuijpers, Groningen, The Netherlands E. Wine, Edmonton, Canada
08:20 - 08:40	2: Epidemiology: What links diet to IBD J. Lindsay, London, United Kingdom
08:40 - 09:00	3: What can we learn about the role of diet in IBD from across the globe? L. Godny, Petah Tikva, Israel
09:00 - 09:20	4: Is the diet affecting my IBD or is IBD affecting my diet? E. Wine, Edmonton, Canada
09:20 - 09:30	5: Abstract presentation: Processed and ultra-processed food and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD) C. Dong, Bramois, Switzerland
09:30 - 09:50	Break
09:50 - 10:50	Session 2: Practicalities and pitfalls of dietary therapy in IBD C. Wall, Christchurch, New Zealand A. Ibarra, London, United Kingdom
09:50 - 10:10	6: Micronutrient sufficiency in IBD C. Wall, Christchurch, New Zealand
10:10 - 10:30	7: (Sarcopenic) obesity in IBD M. Campmans-Kuijpers, Groningen, The Netherlands
10:30 - 10:50	8: Beware of dietary therapy: Dangers of diets used to treat IBD D. O'Hanlon, London, United Kingdom
10:50 - 11:10	Break

11:10 - 12:25	Session 3: MDT: More than just the MD? L. Godny, Petah Tikva, Israel E. Halmos, Melbourne, Australia
11:10 - 11:20	9: Abstract presentation: Unpacking the different popular diets for pediatric Crohn's Disease – concerns around nutritional adequacy E. Carmody, Halifax, Canada
11:20- 12:00	10: MDT case discussions M. Adamina, Winterthur, Switzerland A. Ibarra, London, United Kingdom K. Katsanos, Ioannina, Greece D. O'Hanlon, London, United Kingdom
12:00- 12:20	12: Panel Discussion and Q&A M. Adamina, Winterthur, Switzerland A. Ibarra, London, United Kingdom K. Katsanos, Ioannina, Greece D. O'Hanlon, London, United Kingdom
12:20 - 12:25	13: Closing remarks M. Campmans-Kuijpers, Groningen, The Netherlands



European
Crohn's and Colitis
Organisation

ECCO'22 Webcasts



Missed an excellent presentation at the Congress?

- **All ECCO Members:** Watch video recordings of ECCO'22 and past Congresses on the e-CCO Learning Platform

- **All registered ECCO'22 congress participants:** Watch on-demand recordings on the virtual congress platform until the end of May

- Availability is subject to speaker authorisation
- Scientific programme webcasts
- Digital oral presentation webcasts
- Educational programme webcasts

Scan and visit

www.e-learning.ecco-ibd.eu



Industry sponsored satellite symposia

Industry sponsored satellite symposia organised by pharmaceutical companies are open to all congress participants. The programmes of symposia are not affiliated with ECCO and sponsors hold responsibility for the content of their respective programmes.

Industry sponsored satellite symposia – Scientific programme (as per February 9, 2022) **Thursday, February 17, 2022**

abbvie	Satellite Symposium 1a Organiser: AbbVie
11:00 - 12:00	<i>The rise of JAK inhibition...The journey towards the future?</i> R. Panaccione, Calgary, Canada G. Parkes, London, United Kingdom
11:00 - 11:05	<i>Welcome and introduction (including opening video)</i> R. Panaccione, Calgary, Canada
11:05 - 11:14	<i>Defining the UC treatment landscape – How far have we travelled?</i> R. Panaccione, Calgary, Canada G. Parkes, London, United Kingdom
11:14 - 11:23	<i>Understanding JAKs – Selecting the right path?</i> G. Parkes, London, United Kingdom
11:23 - 11:43	<i>Focus on JAKs – The next stage of the UC journey?</i> R. Panaccione, Calgary, Canada
11:43 - 11:57	<i>Panel discussion – Approaching the next destination in UC treatment?</i> R. Panaccione, Calgary, Canada G. Parkes, London, United Kingdom
11:57 - 12:00	<i>Meeting close (including closing video)</i> R. Panaccione, Calgary, Canada

	Satellite Symposium 1b Organiser: Takeda
11:00 - 12:00	Targeting the pathophysiology of Crohn's Disease to optimize clinical outcomes
11:00 - 11:05	Opening, welcome and introductions B. Bressler, Vancouver, Canada
11:05 - 11:15	Treatment selection in Crohn's Disease: clinical and translational pharmacology M. Neurath, Mainz, Germany
11:15 - 11:30	Crohn's Disease is a moving target: Are we ahead of the game? B. Bressler, Vancouver, Canada
11:30 - 11:45	The path towards disease modification in clinical practice P. Dulai, San Diego, United States
11:45 - 12:00	Panel discussion / Q&A All Faculty
Product characteristics	https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf

	Satellite Symposium 1c Organiser: Janssen
11:00 - 12:00	The Big CD Debate: targeting the future M. Allez, Paris, France P. Irving, London, United Kingdom
11:00 - 11:05	Welcome and introduction M. Allez, Paris, France
11:05 - 11:20	CD management in motion: Aiming for transmural healing? M. Daperno, Turin, Italy
11:20 - 11:35	First biologic in CD: Where to start? P. Irving, London, United Kingdom M. Allez, Paris, France
11:35 - 11:50	Case discussion and Q&A C. Reenaers, Liège, Belgium M. Allez, Paris, France M. Daperno, Turin, Italy P. Irving, London, United Kingdom
11:50 - 12:00	Summary and close P. Irving, London, United Kingdom



**Friday,
18th February, 2022**

07h15 – 08h15 (CET)

Role of Foods in Crohn's Disease: Impact on Inflammation and Recovery

Rotem Sigall Boneh

**Recent Findings on the Use of
Crohn's Disease Exclusion Diet
in Clinical Practice**

Prof. Johan van Limbergen

**How Do Microbes Play a Role
in Inflammation and Recovery?**

Dr. Benoit Chassaing

**How Do Food Additives Play a
Role in Inflammation?**

Prof. Eytan Wine

**How Do Fibres Play a Role
in Inflammation and Recovery?**



Satellite Symposium 1d **Organiser: BMS**

11:00 - 12:00	<i>Evolving treatment options for patients with UC</i> A. Dignass, Frankfurt, Germany
11:00 - 11:05	<i>Welcome and introductions</i> A. Dignass, Frankfurt, Germany
11:05 - 11:20	<i>Providing rapid relief and lasting remission in UC with advanced therapeutic options</i> I. Dotan, Tel Aviv, Israel
11:20 - 11:35	<i>MOA and clinical considerations associated with advanced therapies</i> A. Dignass, Frankfurt, Germany
11:35 - 11:45	<i>Long-term safety of advanced therapies</i> J. Lindsay, London, United Kingdom
11:45 - 12:00	<i>Concluding remarks</i> A. Dignass <i>Q&A session</i> All faculty



Satellite Symposium 2a **Organiser: AbbVie**

18:45 - 19:45	<i>The rise of JAK inhibition...The journey towards the future?</i> R. Panaccione, Calgary, Canada
18:45 - 18:52	<i>Welcome and introduction (including opening video)</i> R. Panaccione, Calgary, Canada
18:52 - 19:00	<i>Defining the UC treatment landscape – How far have we travelled?</i> R. Panaccione, Calgary, Canada G. Parkes, London, United Kingdom
19:00 - 19:10	<i>Understanding JAKs – Selecting the right path?</i> G. Parkes, London, United Kingdom
19:10 - 19:20	<i>Focus on JAKs – The next stage of the UC journey?</i> R. Panaccione, Calgary, Canada
19:20 - 19:30	<i>Panel discussion – Approaching the next destination in UC treatment?</i> R. Panaccione, Calgary, Canada G. Parkes, London, United Kingdom
19:30 - 19:45	<i>Meeting close (including closing video)</i> R. Panaccione, Calgary, Canada



Targeting the pathophysiology of Crohn's disease to optimize clinical outcomes

To find out more about Takeda's symposia, please scan here:



THURSDAY 17 FEBRUARY 2022
11:00–12:00 CET



MARKUS NEURATH,
GERMANY

Treatment selection in Crohn's disease: clinical and translational pharmacology



BRIAN BRESSLER,
CANADA

Crohn's disease is a moving target: are we ahead of the game?



PARAMBIR DULAI,
UNITED STATES

The path towards disease modification in clinical practice

Paid advertisement by Takeda Pharmaceutical Company Limited. This event is open to healthcare professionals who attend ECCO 2022. A Takeda-organized symposium during ECCO 2022. This symposium is not affiliated with ECCO. Copyright © 2022 Takeda Pharmaceutical Company Limited. All rights reserved.

January 2022 | VV-MEDMAT-55784



	Satellite Symposium 2b Organiser: Eli Lilly and Company
18:45 - 19:45	<i>Elevating Ulcerative Colitis Treatment Goals – Is it time to expect more?</i> D. Rubin, Chicago, United States
18:45 - 18:55	<i>Rethinking clinical remission and treatment goals</i> D. Rubin, Chicago, United States
18:55 - 19:10	<i>Why bowel urgency remission matters</i> M. Dubinsky, New York, United States
19:10 - 19:25	<i>Why histologic remission matters</i> S. Travis, Oxford, United Kingdom
19:25 - 19:45	<i>Summary and Q&A</i> D. Rubin, Chicago, United States M. Dubinsky, New York, United States S. Travis, Oxford, United Kingdom



To find out more
about Takeda's
symposia, please
scan here:



Paving the way towards better patient outcomes in inflammatory bowel disease

**FRIDAY 18 FEBRUARY 2022
18:40–19:40 CET**



**PETER IRVING,
UNITED KINGDOM**

**The interplay between
therapy efficacy and
patient-reported outcomes
to achieve treatment
goals in IBD**



**URI KOPYLOV,
ISRAEL**

**Tailoring advanced
therapies to patient needs:
a strategic imperative**



**FILIP BAERT,
BELGIUM**

**Addressing patient
preferences in IBD care:
are we making any progress?**

Paid advertisement by Takeda Pharmaceutical Company Limited. This event is open to healthcare professionals who attend ECCO 2022. A Takeda-organized symposium during ECCO 2022. This symposium is not affiliated with ECCO. Copyright © 2022 Takeda Pharmaceutical Company Limited. All rights reserved.

January 2022 | VV-MEDMAT-55783



	Satellite Symposium 2c Organiser: Pfizer
18:45 - 19:45	<i>Navigating the Benefit–Risk Profiles of JAK Inhibitors: A Journey From Current Best Practice to the Use of Artificial Intelligence in UC</i> C. Lees, Edinburgh, United Kingdom
18:45 - 18:50	<i>Welcome and Introductions</i> C. Lees, Edinburgh, United Kingdom
18:50 - 19:00	<i>Making Treatment Decisions in UC: Artificial Intelligence and Machine Learning Technologies in UC</i> C. Lees, Edinburgh, United Kingdom
19:00 - 19:05	<i>Panel discussion</i> C. Lees, Edinburgh, United Kingdom G. D’Haens, Amsterdam, The Netherlands C. Taxonera, Madrid, Spain
19:05 - 19:15	<i>Regulatory Updates for Tofacitinib and Learnings From Rheumatology</i> C. Lees, Edinburgh, United Kingdom
19:15 - 19:25	<i>Determining appropriate patients for treatment with Tofacitinib using conventional statistics tools</i> G. D’Haens, Amsterdam, The Netherlands
19:25 - 19:30	<i>Panel discussion</i> C. Lees, Edinburgh, United Kingdom G. D’Haens, Amsterdam, The Netherlands C. Taxonera, Madrid, Spain
19:30 - 19:40	<i>JAK Inhibitors in Clinical Practice: Updates From Clinical Trials and the Real World</i> C. Taxonera, Madrid, Spain
19:40 - 19:45	<i>Panel discussion</i> C. Lees, Edinburgh, United Kingdom G. D’Haens, Amsterdam, The Netherlands C. Taxonera, Madrid, Spain <i>Summary and Close</i> C. Lees, Edinburgh, United Kingdom



BREAKING THE SILENCE

**ON COMPLEX CROHN'S
PERIANAL FISTULAS**

Elevating Patient Care

**Please join us for a virtual Takeda-organized
satellite symposium**

Friday, February 18, 2022 | 12:40-13:20 CET



Patients' perspectives: What are the unmet needs?

DR. VINCENT DE PARADES

France



Stem cell therapy: From clinical trials to real world

PROF. ODED ZMORA

Israel



**To find out more about Takeda's
symposia, please scan.**


This event is open to healthcare professionals who attend ECCO 2022.
A Takeda-organized symposium during ECCO 2022.
This symposium is not affiliated with ECCO.
Copyright © 2022 Takeda Pharmaceutical Company Limited.
All rights reserved.
Date of preparation: January 2022. VV-MEDMAT-59477



Galápagos		Satellite Symposium 2d Organiser: Galapagos
18:45 - 19:45	<i>UC the bigger picture: introducing JAK1 in practice within a patient-centric approach</i> I. Dotan, Tel Aviv, Israel	
18:45 - 18:50	<i>Welcome and introduction</i> I. Dotan, Tel Aviv, Israel	
18:50 - 19:00	<i>A new perspective: a patient's experiences of HCP communication</i> S. Vermeire, Leuven, Belgium	
19:00 - 19:10	<i>An all-star cast: multidisciplinary insights on a challenging case</i> I. Dotan, Tel Aviv, Israel	
19:10 - 19:30	<i>New on the scene: preferential JAK1 inhibition in practice</i> G. Fiorino, Rome, Italy	
19:30 - 19:45	<i>Discussion and Q&A</i> All, moderated by I. Dotan, Tel Aviv, Israel	
Product characteristics https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf		


		Satellite Symposium 2e Organiser: Takeda
18:45 - 19:45	<i>Targeting the pathophysiology of Crohn's Disease to optimize clinical outcomes</i>	
18:45 - 18:50	<i>Opening, welcome and introductions</i> B. Bressler, Vancouver, Canada	
18:50 - 19:00	<i>Treatment selection in Crohn's Disease: clinical and translational pharmacology</i> M. Neurath, Mainz, Germany	
19:00 - 19:15	<i>Crohn's Disease is a moving target: Are we ahead of the game?</i> B. Bressler, Vancouver, Canada	
19:15 - 19:30	<i>The path towards disease modification in clinical practice</i> P. Dulai, San Diego, United States	
19:30 - 19:45	<i>Panel discussion/Q&A</i> All Faculty	
Product characteristics https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf		

Friday, February 18, 2022

	Satellite Symposium 3b Organiser: Eli Lilly and Company
07:15 - 08:15	<i>Patient-Centered Management of Ulcerative Colitis: The Urgent Patient Need</i> S. Travis, Oxford, United Kingdom
07:15 - 07:20	<i>Welcome & Introduction</i> S. Travis, Oxford, United Kingdom
07:20 - 07:25	<i>Understanding the patient's perspective – Patient on stage</i>
07:25 - 07:40	<i>Understanding the impact of bowel urgency as a key symptom affecting patient's lives</i> S. Schreiber, Kiel, Germany
07:40 - 07:50	<i>How to assess the impact of bowel urgency on patients</i> C. Norton, London, United Kingdom
07:50 - 08:00	<i>Treatment goals - bridging the patient / HCP divide</i> S. Travis, Oxford, United Kingdom
08:00 - 08:15	<i>Interactive Q&A and panel discussion</i> All Faculty

	Satellite Symposium 3d Organiser: Nestlé Health Science
07:15 - 08:15	<i>Role of Foods in Crohn's Disease: Impact on Inflammation and Recovery</i> J. Van Limbergen, Amsterdam, The Netherlands
07:15 - 07:20	<i>Welcome and introduction</i> J. van Limbergen, Amsterdam, The Netherlands
07:20 - 07:32	<i>Recent findings on the use of Crohn's Disease exclusion diet in clinical practice</i> R. Sigall Boneh, Holon, Israel
07:32 - 07:44	<i>How do microbes play a role in Inflammation and recovery?</i> J. van Limbergen, Amsterdam, The Netherlands
07:44 - 07:56	<i>How do food additives play a role in inflammation?</i> B. Chassaing, Clermont-Ferrand, France
07:56 - 08:08	<i>How do fibres play a role in inflammation and recovery?</i> E. Wine, Edmonton, Canada
08:08 - 08:15	<i>Q&A</i> All

	Lunchtime Satellite Symposium LS1 Organiser: AbbVie
12:40 - 13:20	Scoping out healing: What will IL-23 Inhibition bring to the future of CD Management? S. Vermeire, Leuven, Belgium
12:40 - 12:41	Welcome and introduction S. Vermeire, Leuven, Belgium
12:41 - 12:53	Bringing the pathophysiology of Crohn's Disease into focus R. Atreya, Erlangen, Germany
12:53 - 13:05	The scope of evidence in Crohn's Disease: spotlight on mucosal healing S. Vermeire, Leuven, Belgium
13:05 - 13:14	Why ambitious treatment targets are now within our scope P. Bossuyt, Bonheiden, Belgium
13:14 - 13:20	Q&A All

	Lunchtime Satellite Symposium LS2 Organiser: Takeda
12:40 - 13:20	Breaking the silence on complex Crohn's perianal fistulas: Elevating patient care V. de Parades, Paris, France
12:40 - 12:43	Welcome and introductions V. de Parades, Paris, France
12:43 - 12:53	Patient's perspectives: What are the unmet needs? V. de Parades, Paris, France
12:53 - 13:05	Stem cell therapy: From clinical trials to real world O. Zmora, Tel Aviv, Israel
13:05 - 13:20	Panel discussion / Q&A V. de Parades, Paris, France O. Zmora, Tel Aviv, Israel

Product characteristics https://www.ema.europa.eu/en/documents/product-information/alofisel-epar-product-information_en.pdf

Industry sponsored satellite symposia

	Lunchtime Satellite Symposium LS3 Organiser: Arena
12:40 - 13:20	<i>From theory to practice: Adapting guidance to meet patients-specific needs and goals in UC management</i> J. Colombel, New York, United States M. Dubinsky, New York, United States
12:40 - 12:42	<i>Welcome and introductions</i> J. Colombel, New York, United States
12:42 - 13:02	<i>Setting the bar: Current treatment targets and options</i> J. Colombel, New York, United States
13:02 - 13:09	<i>Preparing for more: UC management for family planning</i> M. Dubinsky, New York, United States
13:09 - 13:16	<i>Rising to the challenge: Special considerations for older patients with UC</i> J. Colombel, New York, United States
13:16 - 13:20	<i>Summary and close remarks</i> M. Dubinsky, New York, United States
Product characteristics	https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf

	Lunchtime Satellite Symposium LS4 Organiser: Celltrion Healthcare
12:40 - 13:20	<i>Emerging Priorities in IBD Care: Switching and Monotherapy with Subcutaneous Infliximab</i> W. Reinisch, Vienna, Austria
12:40 - 12:45	<i>Welcome Remarks</i> W. Reinisch, Vienna, Austria
12:45 - 13:00	<i>From the Frontlines of IBD Care: Subcutaneous Infliximab as Monotherapy</i> S. Ben-Horin, Tel Aviv, Israel
13:00 - 13:15	<i>Insights from the Field: Real-world Switching Experience with subcutaneous Infliximab</i> F. Cummings, Southampton, United Kingdom
13:15 - 13:20	<i>Closing remarks</i> W. Reinisch, Vienna, Austria
Product characteristics	https://www.ema.europa.eu/en/documents/product-information/remsim-a-epar-product-information_en.pdf

	Lunchtime Satellite Symposium LS5 Organiser: Janssen
12:40 - 13:20	<i>Winter warmer: Hot topics in ulcerative colitis</i> T. Raine, Cambridge, United Kingdom
12:40 - 12:45	<i>Welcome and introduction</i> T. Raine, Cambridge, United Kingdom
12:45 - 13:10	<i>What are the clinical dilemmas in UC?</i> E. Louis, Liège, Belgium A. Moschen, Linz, Austria T. Raine, Cambridge, United Kingdom
13:10 - 13:15	<i>Q&A session</i> Moderator: T. Raine, Cambridge, United Kingdom All other faculty: A. Moschen, Linz, Austria E. Louis, Liège, Belgium
13:15 - 13:20	<i>Summary and close</i> T. Raine, Cambridge, United Kingdom
	Lunchtime Satellite Symposium 4a Organiser: AbbVie
18:40 - 19:20	<i>Scoping out healing: What will IL-23 Inhibition bring to the future of CD Management?</i> S. Vermeire, Leuven, Belgium
18:40 - 18:41	<i>Welcome and introduction</i> S. Vermeire, Leuven, Belgium
18:41 - 18:53	<i>Bringing the pathophysiology of Crohn's Disease into focus</i> R. Atreya, Erlangen, Germany
18:53 - 19:05	<i>The scope of evidence in Crohn's Disease: spotlight on mucosal healing</i> S. Vermeire, Leuven, Belgium
19:05 - 19:14	<i>Why ambitious treatment targets are now within our scope</i> P. Bossuyt, Bonheiden, Belgium
19:14 - 19:20	<i>Q&A</i> All



Satellite Symposium 4b **Organiser: Takeda**


18:40 - 19:40	<i>Paving the way towards better patient outcomes in inflammatory bowel disease</i>
18:40 - 18:45	<i>Opening, welcome and introductions</i> F. Baert, Roeselare, Belgium
18:45 - 19:00	<i>The interplay between therapy efficacy and patient-reported outcomes to achieve treatment goals in IBD</i> P. Irving, London, United Kingdom
19:00 - 19:15	<i>Tailoring advanced therapies to patient needs: a strategic imperative</i> U. Kopylov, Ramat Gan, Israel
19:15 - 19:30	<i>Addressing patient preferences in IBD care: Are we making any progress?</i> F. Baert, Roeselare, Belgium
19:30 - 19:40	<i>Panel discussion/Q&A</i> All Faculty

Product characteristics https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf




Satellite Symposium 4c **Organiser: Janssen**

18:40 - 19:40	<i>Pioneering the IL-23 pathway</i> S. Ghosh, Cork, Ireland
18:40 - 18:45	<i>Welcome and introduction</i> S. Ghosh, Cork, Ireland
18:45 - 19:55	<i>Targeting the IL-23 pathway: From mechanism to clinical reality?</i> R. Atreya, Erlangen, Germany
19:55 - 19:05	<i>IL-23 antagonists in Crohn's Disease</i> B. Sands, New York, United States
19:05 - 19:20	<i>IL-23 antagonists in Ulcerative Colitis</i> G. D'Haens, Amsterdam, The Netherlands
19:20 - 19:37	<i>Where present and future meet</i> Moderator: S. Ghosh, Cork, Ireland All faculty: B. Sands, New York, United States R. Atreya, Erlangen, Germany G. D'Haens, Amsterdam, The Netherlands
19:37 - 19:40	<i>Summary and close</i> S. Ghosh, Cork, Ireland

	Satellite Symposium 4d Organiser: Eli Lilly and Company
18:40 - 19:40	<i>Elevating Ulcerative Colitis Treatment Goals – Is it time to expect more?</i> D. Rubin, Chicago, United States
18:40 - 18:50	<i>Rethinking clinical remission and treatment goals</i> D. Rubin, Chicago, United States
18:50 - 19:05	<i>Why bowel urgency remission matters</i> M. Dubinsky, New York, United States
19:05 - 19:20	<i>Why histologic remission matters</i> S. Travis, Oxford, United Kingdom
19:20 - 19:40	<i>Summary and Q&A</i> D. Rubin, Chicago, United States M. Dubinsky, New York, United States S. Travis, Oxford, United Kingdom

	Satellite Symposium 4e Organiser: Pfizer
18:40 - 19:40	<i>Navigating the Benefit–Risk Profiles of JAK Inhibitors: A Journey From Current Best Practice to the Use of Artificial Intelligence in UC</i> C. Lees, Edinburgh, United Kingdom
18:40 - 18:45	<i>Welcome and Introductions</i> C. Lees, Edinburgh, United Kingdom
18:45 - 18:55	<i>Making Treatment Decisions in UC: Artificial Intelligence and Machine Learning Technologies in UC</i> C. Lees, Edinburgh, United Kingdom
18:55 - 19:00	<i>Panel discussion</i> C. Lees, Edinburgh, United Kingdom G. D’Haens, Amsterdam, The Netherlands C. Taxonera, Madrid, Spain
19:00 - 19:10	<i>Regulatory Updates for Tofacitinib and Learnings From Rheumatology</i> C. Lees, Edinburgh, United Kingdom
19:10 - 19:20	<i>Determining appropriate patients for treatment with Tofacitinib using conventional statistics tools</i> G. D’Haens, Amsterdam, The Netherlands
19:20 - 19:25	<i>Panel discussion</i> C. Lees, Edinburgh, United Kingdom G. D’Haens, Amsterdam, The Netherlands C. Taxonera, Madrid, Spain
19:25 - 19:35	<i>JAK Inhibitors in Clinical Practice: Updates From Clinical Trials and the Real World</i> C. Taxonera, Madrid, Spain
19:35 - 19:40	<i>Panel discussion</i> C. Lees, Edinburgh, United Kingdom G. D’Haens, Amsterdam, The Netherlands C. Taxonera, Madrid, Spain <i>Summary and Close</i> C. Lees, Edinburgh, United Kingdom

Industry sponsored satellite symposia – Educational programme (as of February 9, 2022) Thursday, February 17, 2022 – S-ECCO IBD Masterclass

	Satellite Symposium Organiser: Takeda
11:45 - 12:45	Cell-mediated closure in complex Crohn's perianal fistulas: Learning from real-world evidence! D. Hahnloser, Lausanne, Switzerland
11:45 - 11:50	Welcome and introduction D. Hahnloser, Lausanne, Switzerland
11:50 - 12:00	A bird's eye view of the treatment landscape D. Hahnloser, Lausanne, Switzerland
12:00 - 12:10	What can real-world evidence teach us? D. Hahnloser, Lausanne, Switzerland
12:10 - 12:30	We need closure! Tips and tricks to get there D. Hahnloser, Lausanne, Switzerland
12:30 - 12:40	Q&A D. Hahnloser, Lausanne, Switzerland
12:40 - 12:45	Summary and close D. Hahnloser, Lausanne, Switzerland

Product https://www.ema.europa.eu/en/documents/product-characteristics/information/alofisel-epar-product-information_en.pdf

Thursday, February 17, 2022 – N-ECCO Network Meeting

	Satellite Symposium Organiser: Takeda
12:45 - 13:45	Better together: Empowering patients to self-manage their IBD
12:45 - 12:50	Welcome and introduction U. Lovén Wickman, Kalmar, Sweden
12:50 - 13:05	Why does self-management matter? U. Lovén Wickman, Kalmar, Sweden
13:05 - 13:20	Practical tips for patient empowerment M. Andersson, Borås, Sweden
13:20 - 13:40	Q&A All
13:40 - 13:45	Summary and close U. Lovén Wickman, Kalmar, Sweden M. Andersson, Borås, Sweden

Thursday, February 17, 2022 – ClinCom Educational Symposium

 abivax	Satellite Symposium Organiser: Abivax
12:00 - 13:00	<i>ABX464, a novel anti-inflammatory drug-candidate for the treatment of ulcerative colitis entering into phase 3 clinical testing</i> B. Sands, New York, United States
12:00 - 12:05	<i>Welcome and opening remarks</i> B. Sands, New York, United States
12:05 - 12:20	<i>The continued need to develop novel drugs for ulcerative colitis</i> W. Sandborn, La Jolla, United States
12:20 - 12:35	<i>ABX464 novel mechanism of action: Upregulation of the anti-inflammatory microRNA miR-124</i> D. Scherrer, Montpellier, France
12:35 - 12:50	<i>Safety and efficacy of ABX464 in ulcerative colitis and the implementation of a global phase 3 program</i> B. Sands, New York, United States
12:50 - 13:00	<i>Questions & answers</i> All



European
Crohn's and Colitis
Organisation

Copenhagen
Denmark

Inflammatory Bowel Diseases

Announcement 2023



18th Congress of ECCO
Bella Center Copenhagen
March 1-4, 2023



Scan and visit

www.ecco-ibd.eu

Corporate sponsors

(as of January 15, 2022)

ECCO gratefully acknowledges the support of the following ECCO Corporate Members:

abbvie

AMGEN®



AstraZeneca 

 Bristol Myers
Squibb™

 BÜHLMANN

 HEALTHCARE
CELLTRION





Imprint

Publisher

ECCO – European Crohn's and Colitis Organisation

OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH
Ungargasse 6/13, 1030 Vienna, Austria

Phone: +43-(0)1-710 22 42

Fax: +43-(0)1-710 22 42-001

E-Mail: ecco-congress@ecco-ibd.eu

Web: www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation





DrFalk

INNOVATION DRIVES EVERYTHING

**Dr. Falk Pharma – the experts in
digestive and metabolic medicine**

Innovation drives everything we do. As specialists in digestive and metabolic medicine, we bring physicians, scientists, and patients together to develop new and powerful approaches to patient care. We continuously listen to your needs and respond with treatment solutions that provide real improvement to patients' health and well-being. As a research-based family business with global presence, we are investing in trials in IBD, PSC, NASH and Celiac Disease with new compounds. **Our aim is to help transform clinical practice, one life-changing discovery at a time.**

Together we know more. Together we do more.

Dr. Falk Pharma GmbH
Leinenweberstr. 5 | 79108 Freiburg | Germany
www.dralkpharma.com

Paid advertisement by Dr. Falk Pharma

EXPLORING NEW AREAS TO HELP PATIENTS NAVIGATE IBD

We're proud to be part of ECCO 2022 and share a common goal with all participants—to do more for people with IBD. At Arena, we have an “all in” approach to developing investigational gastrointestinal drugs* that address unmet patient needs in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.

VISIT ARENA PHARMACEUTICALS AT OUR VIRTUAL BOOTH

*Arena is a clinical stage pharmaceutical company that does not have any medicines or products approved for use by any health authority.

© 2022 Arena
Pharmaceuticals, Inc.
All Rights Reserved.
MLR-ALL-UC-0020

ARENA
PHARMACEUTICALS®
Care More. Act Differently.